Continuous flow manufacturing process of 1,4-dithiothreitol to meet its increasing demand for disease test kits.

点击翻译按钮获取中文摘要

The partnership between BioVectra Inc. and Prof. André B. Charette-Université de Montréal is a milestone towards an in-house Canadian manufacturing of high quality compounds in order to meet an increasing Canadian market demand. This approach will allow to mitigate Canada's heavy reliance on foreign suppliers and hence empower the Canadian economy and health care system. Specifically, the goal of this partnership is to develop an efficient synthetic route under continuous flow conditions to manufacture and supply on demand 1,4-dithiothreitol (DTT) to meet the rapidly expanding needs of the global and Canadian market. This reagent is routinely used as a key component in assays and in particular in COVID-19 testing kits where the demand has increased exponentially in the last year. The optimal synthetic procedure using continuous flow techniques will be develop within the Center for Continuous Flow Synthesis (CCFS), a state of the art laboratory located at Université de Montréal. The optimized process will then be effectively transfer to BioVectra's continuous flow large scale manufacturing facility for mass production and market distribution of DTT. This partnership is a turn-key solution to rapidly, safely and effectively supply the Canadian market with the crucially needed DTT. Through this partnership, trainees will gain experience in solving real world problems and well thought after pluri-disciplinary knowledge that will promote their successful entrance in the work force.